Cidara Therapeutics Analyst Ratings
Cidara Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/06/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
09/22/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
09/22/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
09/08/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
09/07/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
08/07/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
08/04/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
08/01/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
08/01/2023 | 509.76% | Cantor Fitzgerald | → $5 | Reiterates | Overweight → Overweight |
06/26/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
05/15/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
05/12/2023 | 265.85% | Needham | → $3 | Reiterates | Buy → Buy |
04/18/2023 | 265.85% | Needham | → $3 | Reiterates | → Buy |
03/24/2023 | 631.71% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
03/23/2023 | 631.71% | HC Wainwright & Co. | $6.5 → $6 | Maintains | Buy |
03/08/2023 | 509.76% | Cantor Fitzgerald | → $5 | Reiterates | → Overweight |
03/01/2023 | 692.68% | HC Wainwright & Co. | → $6.5 | Reiterates | → Buy |
01/25/2023 | 692.68% | HC Wainwright & Co. | $6 → $6.5 | Maintains | Buy |
05/12/2022 | 631.71% | HC Wainwright & Co. | $7.5 → $6 | Maintains | Buy |
09/22/2021 | 875.61% | Aegis Capital | $9 → $8 | Maintains | Buy |
09/22/2021 | — | WBB Securities | Upgrades | Buy → Strong Buy | |
03/04/2021 | 997.56% | Aegis Capital | → $9 | Initiates Coverage On | → Buy |
08/26/2020 | 509.76% | Citigroup | $6 → $5 | Maintains | Buy |
03/05/2020 | 631.71% | Needham | $10 → $6 | Maintains | Buy |
12/04/2019 | 662.2% | WBB Securities | → $6.25 | Upgrades | Speculative Buy → Buy |
09/04/2019 | — | Wedbush | Upgrades | Neutral → Outperform | |
06/06/2019 | 631.71% | Oppenheimer | → $6 | Initiates Coverage On | → Outperform |
05/17/2019 | 143.9% | Wedbush | $7 → $2 | Downgrades | Outperform → Neutral |
03/01/2019 | 753.66% | Wedbush | $12 → $7 | Maintains | Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/06/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
09/22/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 购买 → 购买 |
09/22/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
09/08/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 购买 → 购买 |
09/07/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
08/07/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
08/04/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 购买 → 购买 |
08/01/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
08/01/2023 | 509.76% | 坎托·菲茨杰拉德 | → 5 美元 | 重申 | 超重 → 超重 |
06/26/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
05/15/2023 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | 购买 → 购买 |
05/12/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | 购买 → 购买 |
04/18/2023 | 265.85% | 尼德姆 | → 3 美元 | 重申 | → 购买 |
2023 年 3 月 24 日 | 631.71% | HC Wainwright & Co. | → 6 美元 | 重申 | → 购买 |
03/23/2023 | 631.71% | HC Wainwright & Co. | 6.5 美元 → 6 美元 | 维护 | 买 |
03/08/2023 | 509.76% | 坎托·菲茨杰拉德 | → 5 美元 | 重申 | → 超重 |
03/01/2023 | 692.68% | HC Wainwright & Co. | → 6.5 美元 | 重申 | → 购买 |
01/25/2023 | 692.68% | HC Wainwright & Co. | 6 美元 → 6.5 美元 | 维护 | 买 |
05/12/2022 | 631.71% | HC Wainwright & Co. | 7.5 美元 → 6 美元 | 维护 | 买 |
2021 年 9 月 22 日 | 875.61% | 宙斯盾资本 | 9 美元 → 8 美元 | 维护 | 买 |
2021 年 9 月 22 日 | — | WBB 证券 | 升级 | 买入 → 强势买入 | |
2021 年 4 月 3 日 | 997.56% | 宙斯盾资本 | → 9 美元 | 启动覆盖范围开启 | → 购买 |
08/26/2020 | 509.76% | 花旗集团 | 6 美元 → 5 美元 | 维护 | 买 |
03/05/2020 | 631.71% | 尼德姆 | 10 美元 → 6 美元 | 维护 | 买 |
2019 年 4 月 12 日 | 662.2% | WBB 证券 | → 6.25 美元 | 升级 | 投机性买入 → 买入 |
09/04/2019 | — | Wedbush | 升级 | 中性 → 跑赢大盘 | |
2019 年 6 月 6 日 | 631.71% | 奥本海默 | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
05/17/2019 | 143.9% | Wedbush | 7 美元 → 2 美元 | 降级 | 跑赢大盘 → 中性 |
03/01/2019 | 753.66% | Wedbush | 12 美元 → 7 美元 | 维护 | 跑赢大盘 |
What is the target price for Cidara Therapeutics (CDTX)?
Cidara Therapeutics(CDTX)的目标价格是多少?
The latest price target for Cidara Therapeutics (NASDAQ: CDTX) was reported by HC Wainwright & Co. on November 6, 2023. The analyst firm set a price target for $6.00 expecting CDTX to rise to within 12 months (a possible 631.71% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月6日公布了Cidara Therapeutics(纳斯达克股票代码:CDTX)的最新目标股价。该分析公司将目标股价定为6.00美元,预计CDTX将在12个月内升至12个月内(可能上涨631.71%)。去年有18家分析公司公布了评级。
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
分析师对Cidara Therapeutics(CDTX)的最新评级是多少?
The latest analyst rating for Cidara Therapeutics (NASDAQ: CDTX) was provided by HC Wainwright & Co., and Cidara Therapeutics reiterated their buy rating.
HC Wainwright & Co. 对Cidara Therapeutics(纳斯达克股票代码:CDTX)的最新分析师评级由HC Wainwright & Co. 提供,Cidara Therapeutics重申了买入评级。
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Cidara Therapeutics(CDTX)的下一个分析师评级何时公布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Cidara Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Cidara Therapeutics的最新评级是在2023年11月6日公布的,因此您应该预计下一个评级将在2024年11月6日左右公布。
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
分析师对 Cidara Therapeutics (CDTX) 的评级正确吗?
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $0.00 to $6.00. The current price Cidara Therapeutics (CDTX) is trading at is $0.82, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但重申了最新的Cidara Therapeutics(CDTX)评级,目标股价为0.00美元至6.00美元。Cidara Therapeutics(CDTX)目前的交易价格为0.82美元,在分析师的预测区间内。